Aniline

Aniline

SCHEMBL4155229

Nc1cccc(Cl)c1[N+](=O)[O-].Nc1ccccc1

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.42
ALDH1A1 P00352 6/20 0.42
PDE7A Q13946 6/20 0.41
NPY1R P25929 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
NPC1 O15118 1/20 0.37
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37
XBP1 P17861 1/20 0.37
HTT P42858 1/20 0.37
RAB9A P51151 1/20 0.37
TLR9 Q9NR96 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
NR4A2 P43354 1/20 0.37
GRIN2D O15399 1/20 0.37
GRIN3B O60391 1/20 0.37
GRIN1 Q05586 1/20 0.37
GRIN2A Q12879 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL203912 0.91 TSHR (0.44) TSHRALDH1A1PDE7ANPY1RSMN1; SMN2
SCHEMBL11901717 0.79 ALDH1A1 (0.45) TSHRALDH1A1PDE7ANPY1RSMN1; SMN2
SCHEMBL26921171 0.78 PTGER4 (0.41) TSHRALDH1A1PDE7ASMN1; SMN2NPC1
SCHEMBL670917 0.77 TSHR (0.58) TSHRALDH1A1LMNAHPGDTDP1
SCHEMBL11551067 0.77 TDP1 (0.52) TSHRALDH1A1PDE7ASMN1; SMN2LMNA
SCHEMBL3390153 0.77 TDP1 (0.52) TSHRALDH1A1PDE7ASMN1; SMN2LMNA
Aniline SCHEMBL10525035 0.77 ALDH1A1 (0.47) TSHRALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL20535320 0.76 HPGD (0.59) TSHRALDH1A1PDE7ASMN1; SMN2NPC1
Hydrochloric Acid SCHEMBL5914596 0.75 TDP1 (0.50) TSHRALDH1A1PDE7ASMN1; SMN2LMNA
Aniline SCHEMBL4189701 0.74 TSHR (0.55) TSHRALDH1A1PDE7ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090192169-A1 Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators ASTRAZENECA AB (SE) 2009-07-30 US disclosed
EP-2004613-A2 BICYCLIC BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS AstraZeneca AB (SE) 2008-12-24 EP disclosed
WO-2007115077-A2 BICYCLIC BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS ASTRAZENECA AB (SE) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192169-A1 Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators GRM1, GRIN1, GRM2 TSHR 467/4885ALDH1A1 1006/4885PDE7A 1246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.